Summary of Geometric Mean Titers, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 Evaluable Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])
SARS-CoV-2 neutralization assay - NT50 (titer)	1/Prevax	ALL	155	~~11~~22.2 (~~10.3, 12.3~~20.7, 23.8)	136	~~10.5~~ (~~9.9, 11~~21.1 (20.2, 22.0)	29	~~11.2~~ (~~8.9, 14.0~~)22.3 (18.7, 26.7)	24	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)
		POS	8	~~54.1~~ (~~19.7, 148.7~~)61.0 (26.4, 140.8)	5	~~38.6~~ (~~6.4, 232~~45.3 (10.2, 201.9)	1	251.0 (NE, NE)	0	NE (NE, NE)
		NEG	146	~~10.3~~ (~~9.7, 10.9~~)21.0 (20.0, 22.1)	131	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)	27	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)	24	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)
	2/1 Month	ALL	207	~~1283.0~~ (~~1139.6, 1444.5~~)1296.4 (1160.4, 1448.4)	185	~~730.8~~ (~~646.7, 825~~733.6 (651.0, 826.8)	36	~~15.1~~ (~~10.7, 21.4~~)27.3 (20.9, 35.6)	32	~~10~~21.5 (19.5, 23.7 ~~(9.3, 12.4~~)
		POS	10	2342.2 (1308.7, 4191.8)	8	1439.2 (727.1, 2848.7)	2	191.0 (1.2, 30873.6)	1	~~10.0~~20.5 (NE, NE)
		NEG	192	~~1239~~1253.2 (~~1096~~1118.6, ~~1400.5~~1404.1)	177	~~708~~711.6 (630.7 ~~(626.4~~, 802.~~0~~9)	33	~~13.1~~ (~~9.7, 17.7~~)24.4 (19.4, 30.8)	31	~~10~~21.5 (19.5, 23.8 ~~(9.3, 12.5~~)

Abbreviations: COVID-19 = coronavirus disease 2019; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein–binding; NE = not estimable; NEG = negative; NT50 = 50% neutralizing titer; POS = positive; Prevax = before vaccination; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Summary of Geometric Mean Titers, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 Evaluable Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])

a. Protocol-specified timing for blood sample collection.
b. POS = positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19. NEG = negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19. ALL = irrespective of baseline SARS-CoV-2 status, including missing baseline status.
c. n = Number of subjects with valid and determinate assay results for the specified assay at the given dose/sampling time point.
d. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
PFIZER CONFIDENTIAL SDTM Creation: ~~25MAR2021 (23:25~~09FEB2022 (12:16) Source Data: adva Table Generation: ~~27MAR2021 (04:54~~09FEB2022 (18:59)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./~~nda2~~nda3 unblinded/C4591001 BLA_IMM/adva s001 gm ped eval

Summary of Geometric Mean Titers, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 All-Available Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])
SARS-CoV-2 neutralization assay - NT50 (titer)	1/Prevax	ALL	156	~~11~~22.2 (~~10.2, 12.3~~20.7, 23.8)	140	~~10.5~~ (~~9.9, 11~~21.1 (20.2, 22.0)	29	~~11.2~~ (~~8.9, 14.0~~)22.3 (18.7, 26.7)	25	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)
		POS	8	~~54.1~~ (~~19.7, 148.7~~)61.0 (26.4, 140.8)	5	~~38.6~~ (~~6.4, 232~~45.3 (10.2, 201.9)	1	251.0 (NE, NE)	0	NE (NE, NE)
		NEG	147	~~10.3~~ (~~9.7, 10.9~~)21.0 (20.0, 22.1)	135	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)	27	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)	25	~~10.0~~ (~~10.0, 10.0~~)20.5 (20.5, 20.5)
	2/1 Month	ALL	208	~~1284.4~~ (~~1141.4, 1445~~1297.7 (1162.2, 1449.1)	190	~~726.3~~ (~~643.9, 819~~729.0 (648.0, 820.1)	36	~~15.1~~ (~~10.7, 21.4~~)27.3 (20.9, 35.6)	34	~~10.7~~ (~~9.3, 12.2~~)21.4 (19.6, 23.5)
		POS	10	2342.2 (1308.7, 4191.8)	8	1439.2 (727.1, 2848.7)	2	191.0 (1.2, 30873.6)	1	~~10.0~~20.5 (NE, NE)
		NEG	193	~~1240.9~~ (~~1098.7, 1401.5~~)1254.8 (1120.6, 1405.1)	182	~~704.7~~ (~~624.1, 795.9~~)707.5 (628.2, 796.8)	33	~~13.1~~ (~~9.7, 17.7~~)24.4 (19.4, 30.8)	33	~~10.7~~ (~~9.3, 12.3~~21.5 (19.5, 23.6)

Abbreviations: COVID-19 = coronavirus disease 2019; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein–binding; NE = not estimable; NEG = negative; NT50 = 50% neutralizing titer; POS = positive; Prevax = before vaccination; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Summary of Geometric Mean Titers, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 All-Available Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])	n[c]	GMT[d] (95% CI[d])

a. Protocol-specified timing for blood sample collection.
b. POS = positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19. NEG = negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19. ALL = irrespective of baseline SARS-CoV-2 status, including missing baseline status.
c. n = Number of subjects with valid and determinate assay results for the specified assay at the given dose/sampling time point.
d. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Summary of Geometric Mean Fold Rise From Before Vaccination to Each Subsequent Time Point, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 Evaluable Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])
SARS-CoV-2 neutralization assay - NT50 (titer)	2/1 Month	ALL	154	~~118.3~~ (~~101~~60.4~~, 137.9~~ (52.5, 69.4)	135	~~71.2~~ (~~61.3, 82.7~~)35.5 (30.6, 41.0)	29	1.4~~4~~ (~~1.~~2 (0~~, 1~~.9, 1.6)	24	1.1 (0.9, 1.~~3~~2)
		POS	8	~~47.6~~ (~~26.4, 86~~42.2 (24.8, 72.0)	5	~~47.1~~40.2 (3.~~1, 721.4~~7, 437.7)	1	1.1 (NE, NE)	0	NE (NE, NE)
		NEG	145	~~125.0~~ (~~106~~61.9~~, 146.2~~ (53.6, 71.5)	130	~~72~~35.3 (~~62.9, 83.2~~30.7, 40.6)	27	1.4~~4~~ (~~2~~ (0.9, 1.~~0, 2.0~~6)	24	1.1 (0.9, 1.~~3~~2)

Abbreviations: COVID-19 = coronavirus disease 2019; GMFR = geometric mean fold rise; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein–binding; NE = not estimable; NEG = negative; NT50 = 50% neutralizing titer; POS = positive; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

a. Protocol-specified timing for blood sample collection.

b. POS = positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19. NEG = negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19. ALL = irrespective of baseline SARS-CoV-2 status, including missing baseline status.

c. n = Number of subjects with valid and determinate assay results for the specified assay both prevaccination time points and at the given dose/sampling time point.

d. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

PFIZER CONFIDENTIAL SDTM Creation: ~~25MAR2021 (23:25~~09FEB2022 (12:16) Source Data: adva Table Generation: ~~27MAR2021 (04:54~~09FEB2022 (18:59)

(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./~~nda2~~nda3_unblinded/C4591001_BLA_IMM/adva_s002_gmfr_ped_eval

Summary of Geometric Mean Fold Rise From Before Vaccination to Each Subsequent Time Point, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 All-Available Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])
SARS-CoV-2 neutralization assay - NT50 (titer)	2/1 Month	ALL	155	~~118~~60.5 (~~101~~52.7, ~~138.0~~69.4)	139	~~70~~35.0 (30.3 ~~(60.7, 81.5,~~ 40.4)	29	1.~~4~~ ~~(1.~~2 (0, ~~1.~~9, 1.6)	25	1.1 (0.9, 1.~~3~~2)
		POS	8	~~47.6 (26.4, 86~~42.2 (24.8, 72.0)	5	~~47.1~~40.2 (3.~~1, 721.4~~7, 437.7)	1	1.1 (NE, NE)	0	NE (NE, NE)
		NEG	146	~~125.2 (107.2, 146.3)~~62.0 (53.7, 71.6)	134	~~71~~34.8 (30.4 ~~(62.2, 81.9,~~ 40.0)	27	1.~~4~~ ~~(~~2 (0.9, 1.~~0, 2.0~~6)	25	1.1 (0.9, 1.~~3~~2)

Abbreviations: COVID-19 = coronavirus disease 2019; GMFR = geometric mean fold rise; LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein–binding; NE = not estimable; NEG = negative; NT50 = 50% neutralizing titer; POS = positive; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

a. Protocol-specified timing for blood sample collection.

b. POS = positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19. NEG = negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19. ALL = irrespective of baseline SARS-CoV-2 status, including missing baseline status.

c. n = Number of subjects with valid and determinate assay results for the specified assay both prevaccination time points and at the given dose/sampling time point.

d. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

PFIZER CONFIDENTIAL SDTM Creation: ~~25MAR2021 (23:25~~09FEB2022 (12:16) Source Data: adva Table Generation: ~~27MAR2021 (06:15~~09FEB2022

Summary of Geometric Mean Fold Rise From Before Vaccination to Each Subsequent Time Point, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 All-Available Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])	n[c]	GMFR[d] (95% CI[d])

(18:59)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./~~nda2~~nda3_unblinded/C4591001_BLA_IMM/adva_s002_gmfr_ped_aai

Summary of Geometric Mean Ratio – NT50 – Comparison of Subjects 12 Through 15 Years of Age to Subjects 16 Through 25 Years of Age (Immunogenicity Subset) – Subjects Without Evidence of Infection up to 1 Month After Dose 2 – Dose 2 Evaluable Immunogenicity Population

		Vaccine Group (as Randomized)					
		BNT162b2 (30 µg)					
		12-15 Years		16-25 Years		12-15 Years/16-25 Years	
Assay	Dose/ Sampling Time Point[a]	n[b]	GMT[c] (95% CI[c])	n[b]	GMT[c] (95% CI[c])	GMR[d] (95% CI[d])	Met Noninferiority Objective[e] (Y/N)
SARS-CoV-2 neutralization assay - NT50 (titer)	2/1 Month	190	~~1239.5~~ ~~(1095.5, 1402.5)~~1253.6 (1117.7, 1406.1)	170	~~705~~708.1 (~~621.4, 800.2~~625.9, 801.1)	1.~~76~~77 (1.~~47~~50, 2.~~10~~09)	Y

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Note: Subjects who had no serological or virological evidence (up to 1 month after receipt of the last dose) of past SARS-CoV-2 infection (ie, N-binding

Summary of Geometric Mean Ratio – NT50 –
Comparison of Subjects 12 Through 15 Years of Age to Subjects 16 Through 25 Years of Age (Immunogenicity Subset) –
Subjects Without Evidence of Infection up to 1 Month After Dose 2 – Dose 2 Evaluable Immunogenicity Population

		Vaccine Group (as Randomized)					
		BNT162b2 (30 µg)					
		12-15 Years		16-25 Years		12-15 Years/16-25 Years	
Assay	Dose/ Sampling Time Point[a]	n[b]	GMT[c] (95% CI[c])	n[b]	GMT[c] (95% CI[c])	GMR[d] (95% CI[d])	Met Noninferiority Objective[e] (Y/N)

antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 were included in the analysis.

a. Protocol-specified timing for blood sample collection.

b. n = Number of subjects with valid and determinate assay results for the specified assay at the given dose/sampling time point.

c. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

d. GMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (Group 1 [12-15 years] – Group 2 [16-25 years]) and the corresponding CI (based on the Student t distribution).

e. Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67.

Number (%) of Subjects Achieving a ≥4-Fold Rise From Before Vaccination to Each Subsequent Time Point, by Baseline SARS-CoV-2 Status – NT50 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Immunogenicity Subset) – Dose 2 Evaluable Immunogenicity Population

			Vaccine Group (as Randomized)							
			BNT162b2 (30 µg)				Placebo			
			12-15 Years		16-25 Years		12-15 Years		16-25 Years	
Assay	Dose/ Sampling Time Point[a]	Baseline SARS-CoV-2 Status[b]	N[c]	n[d] (%) (95% CI[e])	N[c]	n[d] (%) (95% CI[e])	N[c]	n[d] (%) (95% CI[e])	N[c]	n[d] (%) (95% CI[e])
SARS-CoV-2 neutralization assay - NT50 (titer)	2/1 Month	ALL	154	~~151 (98.1)~~ ~~(94~~150 (97.4) (93.5, 99.~~6~~3)	135	~~134 (99~~130 (96.3) (~~95.9, 100.0~~91.6, 98.8)	29	1 (3.4) (0.1, 17.8)	24	~~1 (4~~0 (0.0) (0.0, 14.2) ~~(0.1, 21.1)~~
		POS	8	8 (100.0) (63.1, 100.0)	5	4 (80.0) (28.4, 99.5)	1	0 (0.0) (0.0, 97.5)	0	0 (NE) (NE, NE)
		NEG	145	~~142~~141 (97.~~9~~) ~~(94~~2) (93.1, 99.~~6~~2)	130	~~130 (100.0)~~ ~~(97~~126 (96.9) (92.3, 99.2~~, 100.0~~)	27	1 (3.7) (0.1, 19.0)	24	~~1 (4~~0 (0.0) (0.0, 14.2) ~~(0.1, 21.1)~~

Abbreviations: LLOQ = lower limit of quantitation; NE = not estimable; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Baseline assay results below the LLOQ were set to LLOQ in the analysis.

a. Protocol-specified timing for blood sample collection.

b. POS = positive N-binding antibody result at Visit 1, positive NAAT result at Visit 1, or medical history of COVID-19. NEG = negative N-binding antibody result at Visit 1, negative NAAT result at Visit 1, and no medical history of COVID-19. ALL = irrespective of baseline SARS-CoV-2 status, including missing baseline status

c. N = number of subjects with valid and determinate assay results for the specified assay both before vaccination and at the given dose/sampling time point. These values are the denominators for the percentage calculations.

d. n = Number of subjects with ≥4-fold rise from before vaccination for the given assay at the given dose/sampling time point.

e. Exact 2-sided CI based on the Clopper and Pearson method.

PFIZER CONFIDENTIAL SDTM Creation: ~~25MAR2021 (23:25~~09FEB2022 (12:16) Source Data: adva Table Generation: ~~27MAR2021 (06:29~~09FEB2022 (18:59)

(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./~~nda2~~nda3_unblinded/C4591001_BLA_IMM/adva_s001_4fold_ped_eval

Number (%) of Subjects Achieving a ≥4-Fold Rise From Before Vaccination to Each Subsequent Time Point 1 Month After Dose 2 – NT50 – Comparison of Subjects 12 Through 15 Years of Age to Subjects 16 Through 25 Years of Age (Immunogenicity Subset) – Subjects Without Evidence of Infection up to 1 Month After Dose 2 – Dose 2 Evaluable Immunogenicity Population

		Vaccine Group (as Randomized)					
		BNT162b2 (30 µg)					
		12-15 Years		16-25 Years		Difference	
Assay	Dose/ Sampling Time Point[a]	N[b]	n[c] (%) (95% CI[d])	N[b]	n[c] (%) (95% CI[d])	%[e]	(95% CI[f])
SARS-CoV-2 neutralization assay - NT50 (titer)	2/1 Month	143	~~140~~139 (97.~~9~~) (~~94~~2) (93.0, 99.~~6~~2)	124	~~124 (100.0)~~ (~~97~~120 (96.8) (91.9, 99.1~~, 100.0~~)	~~-2.1~~0.4	(-~~6.0, 0.9~~4.2, 5.5)

Abbreviations: LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
Note: Subjects who had no serological or virological evidence (up to 1 month after receipt of the last dose) of past SARS-CoV-2 infection (ie, N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit up to 1 month after Dose 2 were included in the analysis.
Note: Baseline assay results below the LLOQ were set to LLOQ in the analysis.
a. Protocol-specified timing for blood sample collection.
b. N = number of subjects with valid and determinate assay results for the specified assay both before vaccination and at the given dose/sampling time point. These values are the denominators for the percentage calculations.
c. n = Number of subjects with ≥4-fold rise from before vaccination for the given assay at the given dose/sampling time point.
d. Exact 2-sided CI based on the Clopper and Pearson method.
e. Difference in proportions, expressed as a percentage (12-15 years – 16-25 years).
f. 2-Sided CI, based on the Miettinen and Nurminen method for the difference in proportions, expressed as a percentage.
PFIZER CONFIDENTIAL SDTM Creation: ~~25MAR2021 (23:25~~09FEB2022 (12:16) Source Data: adva Table Generation: ~~27MAR2021 (05:56~~09FEB2022 (18:59)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./~~nda2~~nda3 unblinded/C4591001 BLA_IMM/adva s003 4fold ped eval